IDEX Fundamental Analysis - IDEX BIOMETRICS ASA

Fundamental Rating

Taking everything into account, IDEX scores 1 out of 10 in our fundamental rating. IDEX was compared to 52 industry peers in the Electronic Equipment, Instruments & Components industry. IDEX has a bad profitability rating. Also its financial health evaluation is rather negative. IDEX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

IDEX had negative earnings in the past year.

IDEX had a negative operating cash flow in the past year.

IDEX had negative earnings in each of the past 5 years.

IDEX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -100.76%, IDEX is doing worse than 94.23% of the companies in the same industry.

The Return On Equity of IDEX (-931.96%) is worse than 92.31% of its industry peers.

		Industry Rank	Sector Rank
ROA	-100.76%
ROE	-931.96%
ROIC	N/A

ROA(3y)-119.85%

ROA(5y)-118.87%

ROE(3y)-228.17%

ROE(5y)-196.92%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IDEX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IDEX has more shares outstanding

IDEX has more shares outstanding than it did 5 years ago.

IDEX has a better debt/assets ratio than last year.

2.2 Solvency

IDEX has an Altman-Z score of -3.88. This is a bad value and indicates that IDEX is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -3.88, IDEX is not doing good in the industry: 92.31% of the companies in the same industry are doing better.

IDEX has a Debt/Equity ratio of 1.75. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of IDEX (1.75) is worse than 88.46% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.75
Debt/FCF	N/A
Altman-Z	-3.88

ROIC/WACCN/A

WACC8.22%

2.3 Liquidity

IDEX has a Current Ratio of 1.67. This is a normal value and indicates that IDEX is financially healthy and should not expect problems in meeting its short term obligations.

The Current ratio of IDEX (1.67) is comparable to the rest of the industry.

A Quick Ratio of 0.47 indicates that IDEX may have some problems paying its short term obligations.

IDEX has a worse Quick ratio (0.47) than 88.46% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.67
Quick Ratio	0.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IDEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.99%, which is quite impressive.

Looking at the last year, IDEX shows a very negative growth in Revenue. The Revenue has decreased by -87.72% in the last year.

The Revenue has been growing by 14.73% on average over the past years. This is quite good.

EPS 1Y (TTM)92.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-250%

Revenue 1Y (TTM)-87.72%

Revenue growth 3Y-33.35%

Revenue growth 5Y14.73%

Sales Q2Q%-79.49%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year49.24%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IDEX. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 6.21, which indicates a rather cheap valuation of IDEX.

Based on the Price/Forward Earnings ratio, IDEX is valued cheaply inside the industry as 90.38% of the companies are valued more expensively.

Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, IDEX is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.21

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IDEX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IDEX BIOMETRICS ASA

OSL:IDEX (12/5/2025, 1:25:01 PM)

3.225

+0.2 (+6.44%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupTechnology Hardware & Equipment

GICS IndustryElectronic Equipment, Instruments & Components

Earnings (Last)11-13 2025-11-13

Earnings (Next)02-16 2026-02-16/amc

Inst Owners4.78%

Inst Owner ChangeN/A

Ins Owners37.78%

Ins Owner ChangeN/A

Market Cap56.59M

Revenue(TTM)269.00K

Net Income(TTM)-8.57M

Analysts82.86

Price Target1148.1 (35500%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.21
P/S	20.83
P/FCF	N/A
P/OCF	N/A
P/B	6.09
P/tB	14.04
EV/EBITDA	N/A

EPS(TTM)-6.07

EYN/A

EPS(NY)0.52

Fwd EY16.1%

FCF(TTM)-5.66

FCFYN/A

OCF(TTM)-5.66

OCFYN/A

SpS0.15

BVpS0.53

TBVpS0.23

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-100.76%
ROE	-931.96%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-119.85%

ROA(5y)-118.87%

ROE(3y)-228.17%

ROE(5y)-196.92%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	1.75
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.67
Quick Ratio	0.47
Altman-Z	-3.88

F-Score2

WACC8.22%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)92.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-250%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-87.72%

Revenue growth 3Y-33.35%

Revenue growth 5Y14.73%

Sales Q2Q%-79.49%

Revenue Next Year49.24%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y32.83%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year1659.05%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y67.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y67.27%

OCF growth 3YN/A

OCF growth 5YN/A

IDEX BIOMETRICS ASA / IDEX.OL FAQ

What is the ChartMill fundamental rating of IDEX BIOMETRICS ASA (IDEX.OL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IDEX.OL.

Can you provide the valuation status for IDEX BIOMETRICS ASA?

ChartMill assigns a valuation rating of 2 / 10 to IDEX BIOMETRICS ASA (IDEX.OL). This can be considered as Overvalued.

Can you provide the profitability details for IDEX BIOMETRICS ASA?

IDEX BIOMETRICS ASA (IDEX.OL) has a profitability rating of 0 / 10.

IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

IDEX BIOMETRICS ASA / IDEX.OL FAQ

What is the ChartMill fundamental rating of IDEX BIOMETRICS ASA (IDEX.OL) stock?

Can you provide the valuation status for IDEX BIOMETRICS ASA?

Can you provide the profitability details for IDEX BIOMETRICS ASA?